SCHEMBL4635350

SCHEMBL4635350

COC(=O)C(O)c1c(C)c(S(=O)(=O)c2ccc(F)cc2)c2ccccn12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 3/20 0.41
MAPT P10636 5/20 0.40
ALDH1A1 P00352 4/20 0.40
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HCRTR1 O43613 2/20 0.39
HCRTR2 O43614 2/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
HTT P42858 3/20 0.37
KDM4E B2RXH2 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 1/20 0.37
NOD2 Q9HC29 1/20 0.37
NOD1 Q9Y239 1/20 0.37
MAPK1 P28482 2/20 0.37
NR3C2 P08235 2/20 0.37
GAA P10253 1/20 0.36
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2589640 0.85 HCRTR2 (0.55) MAPTALDH1A1LMNASMN1; SMN2HCRTR1
SCHEMBL4636242 0.79 MAPT (0.45) HTR6MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL2592298 0.79 HCRTR2 (0.45) ALDH1A1LMNASMN1; SMN2HCRTR1HCRTR2
SCHEMBL4635636 0.78 HCRTR1 (0.52) HTR6MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL4635262 0.74 HCRTR1 (0.55) HTR6ALDH1A1HCRTR1HCRTR2MEN1
SCHEMBL4635361 0.72 ALDH1A1 (0.46) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL2591733 0.70 HCRTR2 (0.55) MAPTALDH1A1LMNASMN1; SMN2HCRTR1
SCHEMBL4636941 0.68 ALDH1A1 (0.42) HTR6MAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL4636277 0.67 HCRTR1 (0.43) HTR6MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL4635342 0.65 HTR6 (0.42) HTR6ALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306109-A1 Indolizine Derivatives as Ligands of the Crth2 Receptor ARGENTA DISCOVERY LIMITED (GB) 2008-12-11 US disclosed
EP-1931663-A1 IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR Argenta Discovery Limited (GB) 2008-06-18 EP disclosed
WO-2007031747-A1 IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR ARGENTA DISCOVERY LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306109-A1 Indolizine Derivatives as Ligands of the Crth2 Receptor HRH4, HRH2, HRH3 HTR6 40/4885MAPT 4777/4885ALDH1A1 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.